Entering text into the input field will update the search result below

Prana Bio up 28% following research collaboration with Takeda

  • Thinly traded nano cap Prana Biotechnology (PRAN +28%) is up on a healthy 49x surge in volume. Yesterday, it announced a research collaboration with Takeda Pharmaceuticals International (TKPYY +0.4%) to study the ability of PBT434 to slow or prevent neurodegeneration of the gastrointestinal system, characteristic of Parkinson's disease.
  • The research will explore PBT434's effect on GI dysfunction, including constipation, lowered colon motility and inflammation.
  • A recent paper published in Acta Neuropathologica Communications, suggested that PBT434 may reduce iron-mediated neurodegeneration and alpha-synuclein toxicity by reducing the formation of certain aggregates, freeing rescue neurons to restore motor function.

Recommended For You

About ATHE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ATHE--
Alterity Therapeutics Limited